Obesity drugmaker Novo Nordisk's Q1 profit beats forecast
Novo Nordisk posted on Thursday first-quarter operating profit above analyst forecasts, as the Danish drugmaker races to boost output of its hugely popular weight-loss drug Wegovy and fend off comp...
Novo Nordisk owner to invest $200 million in quantum computing startups
Novo Holdings, the controlling shareholder of Danish obesity drugmaker Novo Nordisk , said on Wednesday it plans to invest around $200 million in quantum computing startups.
What Novo Nordisk's Ozempic Success Means for Denmark
Diabetes and obesity drugs Ozempic and Wegovy have become world famous, generating billions in sales and opening a new market for weight loss drugs. The development of semaglutide, the key ingredie...
FTC challenges 'junk' patents held by 10 drugmakers, including for Novo Nordisk's Ozempic
The agency sent letters to Novo Nordisk, AstraZeneca, Boehringer Ingelheim, Covis Pharma, GlaxoSmithKline, Novartis, Teva Pharmaceuticals, among others.
Should You Invest in Novo Nordisk (NVO) Ahead of Q1 Earnings?
Novo Nordisk's (NVO) revenues in the first quarter of 2024 are expected to have been driven by its diabetes and obesity care product sales, especially Ozempic, Rybelsus and Wegovy.
One dose of Novo Nordisk's Wegovy back in supply, FDA website shows
The U.S. Food and Drug Administration website showed on Monday one dose of Novo Nordisk's weight-loss drug Wegovy is available after being in short supply, while three other doses remained in limit...
Novo Nordisk: Medicare Coverage To Unlock Another Big Market For Wegovy
Novo Nordisk's weight loss drug, Wegovy, has received FDA approval for reducing the risk of major cardiovascular adverse events. Wegovy demonstrated a 20% reduction in the risk of major cardiovascu...
Novo Nordisk hopes to prove Wegovy naysayers wrong
Europe's biggest company, the Danish weight loss drug kingpin Novo Nordisk (NYSE:NVO)'s upcoming results will be squarely focused on the uptake of the flagship Wegovy drug in the US. Analysts have ...
Novo Nordisk (NVO) Stock Sinks As Market Gains: Here's Why
In the latest trading session, Novo Nordisk (NVO) closed at $126.16, marking a -1.93% move from the previous day.
Senate launches investigation into high prices of Ozempic and Wegovy in the U.S.
Before insurance, Novo Nordisk charges about $1,000 per month for Ozempic in the United States. In Germany, the company charges $59 a month for the same drug.
US Senate committee investigates pricing of Novo's Ozempic and Wegovy
A U.S. Senate committee said on Wednesday it had launched an investigation into the prices of Novo Nordisk's diabetes and weight loss drugs Ozempic and Wegovy in the United States.
Missed Out on Novo Nordisk? 2 Healthcare Stocks With Big Catalysts on the Horizon.
Novo Nordisk has achieved tremendous success thanks largely to Ozempic and Wegovy. Vertex Pharmaceuticals is another drugmaker that could soon have two new big winners on the market.
Novo Nordisk (NVO) Boasts Earnings & Price Momentum: Should You Buy?
Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Focus List, a top feature of the Zacks Premium portfolio service.
Why Novo Nordisk Topped the Market Today
The Wegovy and Ozempic maker continues to buy its own shares. It purchased more than 200,000 of them last week.
2 Everlasting Big Pharma Stocks to Buy Today and Hold Forever
Great pharma companies tend to be entrenched in lucrative markets. Vertex Pharmaceuticals is managing to diversify off a strong base.
Related Companies